Barbara Bodner-Adler1, Klaus Bodner2, Oliver Kimberger3, Ksenia Halpern2, Cora Schneidinger2, Peter Haslinger4, Christian Schneeberger4, Reinhard Horvat5, Wolfgang Umek2,6. 1. Department of General Gynecology and Gynecologic Oncology, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria. Barbara.Bodner-Adler@meduniwien.ac.at. 2. Department of General Gynecology and Gynecologic Oncology, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria. 3. Department of Anesthesiology, Medical University of Vienna, Vienna, Austria. 4. Department of Obstetrics and Gynecology, Medical University of Vienna, Vienna, Austria. 5. Institute for Pathology, Medical University of Vienna, Vienna, Austria. 6. Karl Landsteiner Institute of Specialised Obstetrics and Gynecology, Vienna, Austria.
Abstract
INTRODUCTION AND HYPOTHESIS: Abnormalities of connective tissue structure or its repair mechanism may predispose women to pelvic organ prolapse (POP). We hypothesized that the expression of tenascin-X in the uterosacral ligament of postmenopausal women with symptomatic POP is increased compared with postmenopausal women without POP. Furthermore, we identified clinical risk factors associated with POP in our study population. METHODS: We conducted a retrospective case-control study in which 33 postmenopausal women with symptomatic POP ≥ pelvic organ prolapse quantification system (POP-Q) stage II were matched with 33 postmenopausal women without POP. Studied tissue specimens were taken from hysterectomy specimens, and tenascin-X expression was investigated by immunohistochemistry. The immunohistochemical profile of the uterosacral connective tissue of cases and controls was compared. RESULTS: Tenascin-X was expressed in 94% of POP cases and in 91% of controls. Our study failed to show any statistically significant differences in tenascin-X expression between women with and without POP (p = 0.64). However, tenascin-X was significantly more expressed in cases with severe prolapse (POP-Q stage IV) compared with moderate prolapse stages (POP-Q stage II and III) (p = 0.001). Advanced patient age as well as early menopausal age remained independent risk factors associated with POP in multiple logistic regression analysis (p = 0.001). CONCLUSION: No difference could be demonstrated between tenascin-X expression in patients with or without POP. Tenascin-X does not seem to play a major role in the pathogenesis of POP in postmenopausal women.
INTRODUCTION AND HYPOTHESIS: Abnormalities of connective tissue structure or its repair mechanism may predispose women to pelvic organ prolapse (POP). We hypothesized that the expression of tenascin-X in the uterosacral ligament of postmenopausal women with symptomatic POP is increased compared with postmenopausal women without POP. Furthermore, we identified clinical risk factors associated with POP in our study population. METHODS: We conducted a retrospective case-control study in which 33 postmenopausal women with symptomatic POP ≥ pelvic organ prolapse quantification system (POP-Q) stage II were matched with 33 postmenopausal women without POP. Studied tissue specimens were taken from hysterectomy specimens, and tenascin-X expression was investigated by immunohistochemistry. The immunohistochemical profile of the uterosacral connective tissue of cases and controls was compared. RESULTS:Tenascin-X was expressed in 94% of POP cases and in 91% of controls. Our study failed to show any statistically significant differences in tenascin-X expression between women with and without POP (p = 0.64). However, tenascin-X was significantly more expressed in cases with severe prolapse (POP-Q stage IV) compared with moderate prolapse stages (POP-Q stage II and III) (p = 0.001). Advanced patient age as well as early menopausal age remained independent risk factors associated with POP in multiple logistic regression analysis (p = 0.001). CONCLUSION: No difference could be demonstrated between tenascin-X expression in patients with or without POP. Tenascin-X does not seem to play a major role in the pathogenesis of POP in postmenopausal women.
Authors: R C Bump; A Mattiasson; K Bø; L P Brubaker; J O DeLancey; P Klarskov; B L Shull; A R Smith Journal: Am J Obstet Gynecol Date: 1996-07 Impact factor: 8.661
Authors: J Schalkwijk; M C Zweers; P M Steijlen; W B Dean; G Taylor; I M van Vlijmen; B van Haren; W L Miller; J Bristow Journal: N Engl J Med Date: 2001-10-18 Impact factor: 91.245
Authors: Wolf Dietrich; Ksenia Elenskaia; Eva Obermayr; Reinhard Horvat; Klaus Mayerhofer; Wolfgang Umek; Robert Zeillinger; Engelbert Hanzal Journal: Int Urogynecol J Date: 2011-11-29 Impact factor: 2.894
Authors: David D Rahn; Meadow M Good; Shayzreen M Roshanravan; Haolin Shi; Joseph I Schaffer; Ravinder J Singh; R Ann Word Journal: J Clin Endocrinol Metab Date: 2014-06-20 Impact factor: 5.958